Sinphar Pharmaceutical Co Ltd (1734) - Total Assets

Latest as of March 2026: NT$6.42 Billion TWD ≈ $202.30 Million USD

Based on the latest financial reports, Sinphar Pharmaceutical Co Ltd (1734) holds total assets worth NT$6.42 Billion TWD (≈ $202.30 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Sinphar Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.

Sinphar Pharmaceutical Co Ltd - Total Assets Trend (2002–2025)

This chart illustrates how Sinphar Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See Sinphar Pharmaceutical Co Ltd (1734) shareholders funds for net asset value and shareholders' equity analysis.

Sinphar Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Sinphar Pharmaceutical Co Ltd's total assets of NT$6.42 Billion consist of 41.1% current assets and 58.9% non-current assets.

Asset Category	Amount (TWD)	% of Total Assets
Cash & Equivalents	NT$0.00	14.0%
Accounts Receivable	NT$713.86 Million	11.6%
Inventory	NT$724.69 Million	11.8%
Property, Plant & Equipment	NT$0.00	0.0%
Intangible Assets	NT$59.52 Million	1.0%
Goodwill	NT$0.00	0.0%

Asset Composition Trend (2002–2025)

This chart illustrates how Sinphar Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Sinphar Pharmaceutical Co Ltd.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Sinphar Pharmaceutical Co Ltd's current assets represent 41.1% of total assets in 2025, an increase from 0.0% in 2002.
Cash Position: Cash and equivalents constituted 14.0% of total assets in 2025, up from 6.1% in 2002.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 5.0% in 2002.
Asset Diversification: The largest asset category is inventory at 11.8% of total assets.

Sinphar Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Sinphar Pharmaceutical Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Prostemics Co. Ltd KQ:203690	Korea	₩39.70 Billion
ORUM KQ:475830	Korea	₩191.52 Billion
TELIX Pharmaceuticals Ltd AU:TLX	Australia	AU$1.19 Billion
TG Therapeutics Inc NASDAQ:TGTX	USA	$1.53 Billion
Green Cross Holdings Preference Shares KO:005257	Korea	₩4.12 Trillion
Rocket Pharmaceuticals Inc NASDAQ:RCKT	USA	$285.41 Million
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Germany	€40.03 Million
Cybin Inc NEO:CYBN	Canada	CA$290.11 Million

Sinphar Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.37	2.54	1.90
Quick Ratio	1.68	1.84	1.42
Cash Ratio	0.00	0.00	0.00
Working Capital	NT$1.59 Billion	NT$1.61 Billion	NT$1.33 Billion

Sinphar Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Sinphar Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	1.74
Latest Market Cap to Assets Ratio	0.03
Asset Growth Rate (YoY)	-2.3%
Total Assets	NT$6.15 Billion
Market Capitalization	$189.95 Million USD

Valuation Analysis

Below Book Valuation: The market values Sinphar Pharmaceutical Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Sinphar Pharmaceutical Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Sinphar Pharmaceutical Co Ltd (2002–2025)

The table below shows the annual total assets of Sinphar Pharmaceutical Co Ltd from 2002 to 2025.

Year	Total Assets	Change
2025-12-31	NT$6.15 Billion ≈ $193.85 Million	-2.31%
2024-12-31	NT$6.30 Billion ≈ $198.43 Million	+0.75%
2023-12-31	NT$6.25 Billion ≈ $196.94 Million	+1.07%
2022-12-31	NT$6.19 Billion ≈ $194.87 Million	-0.57%
2021-12-31	NT$6.22 Billion ≈ $195.99 Million	+1.53%
2020-12-31	NT$6.13 Billion ≈ $193.03 Million	+3.56%
2019-12-31	NT$5.92 Billion ≈ $186.40 Million	+0.65%
2018-12-31	NT$5.88 Billion ≈ $185.19 Million	-2.73%
2017-12-31	NT$6.04 Billion ≈ $190.39 Million	-2.63%
2016-12-31	NT$6.21 Billion ≈ $195.54 Million	-2.82%
2015-12-31	NT$6.39 Billion ≈ $201.21 Million	-1.20%
2014-12-31	NT$6.46 Billion ≈ $203.65 Million	+13.33%
2013-12-31	NT$5.70 Billion ≈ $179.69 Million	+25.74%
2012-12-31	NT$4.54 Billion ≈ $142.90 Million	-2.22%
2011-12-31	NT$4.64 Billion ≈ $146.14 Million	+24.92%
2010-12-31	NT$3.71 Billion ≈ $116.99 Million	+3.60%
2009-12-31	NT$3.58 Billion ≈ $112.93 Million	-0.25%
2008-12-31	NT$3.59 Billion ≈ $113.20 Million	+13.54%
2007-12-31	NT$3.16 Billion ≈ $99.70 Million	+14.05%
2006-12-31	NT$2.77 Billion ≈ $87.42 Million	-2.26%
2005-12-31	NT$2.84 Billion ≈ $89.45 Million	+20.99%
2004-12-31	NT$2.35 Billion ≈ $73.93 Million	+13.88%
2003-12-31	NT$2.06 Billion ≈ $64.92 Million	+24.74%
2002-12-31	NT$1.65 Billion ≈ $52.05 Million	--

About Sinphar Pharmaceutical Co Ltd

TW:1734 Taiwan Biotechnology

Market Cap

$189.95 Million

NT$6.03 Billion TWD

Market Cap Rank

#16752 Global

#809 in Taiwan

Share Price

NT$31.70

Change (1 day)

+0.00%

52-Week Range

NT$29.71 - NT$33.80

All Time High

NT$65.35